Benzodiazepine receptors in normal human brain, in Parkinson's disease and in progressive supranuclear palsy. 1988

J M Maloteaux, and M A Luabeya, and M A Vanisberg, and E C Laterre, and P M Laduron, and F Javoy-Agid, and Y Agid
Laboratoire de Neurochimie, Université Catholique de Louvain, Brussels, Belgium.

Benzodiazepine receptors have been characterized in human brain. They have been localized mainly in the cerebral cortex and a synaptosomal enrichment was observed after brain fractionation by differential centrifugation. Benzodiazepine receptors were studied in Parkinson's disease and in progressive supranuclear palsy (PSP). In both diseases, the [3H]flunitrazepam specific binding was unchanged when compared to control groups (Bmax and KD values) except in the caudate nucleus of parkinsonian patients where an increase of the specific binding was observed. The subcellular distribution profile of benzodiazepine receptors in Parkinson's disease was similar to that of controls. gamma-Aminobutyric acid (GABA) still enhanced the [3H]flunitrazepam-specific binding (increase of binding affinity), indicating that the functional link between GABA and benzodiazepine receptors remained intact in Parkinson's disease. The present results suggest that benzodiazepine receptors in human striatum are localized on neuronal elements which do not degenerate in Parkinson's disease and PSP.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009928 Organ Specificity Characteristic restricted to a particular organ of the body, such as a cell type, metabolic response or expression of a particular protein or antigen. Tissue Specificity,Organ Specificities,Specificities, Organ,Specificities, Tissue,Specificity, Organ,Specificity, Tissue,Tissue Specificities
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D011963 Receptors, GABA-A Cell surface proteins which bind GAMMA-AMINOBUTYRIC ACID and contain an integral membrane chloride channel. Each receptor is assembled as a pentamer from a pool of at least 19 different possible subunits. The receptors belong to a superfamily that share a common CYSTEINE loop. Benzodiazepine-Gaba Receptors,GABA-A Receptors,Receptors, Benzodiazepine,Receptors, Benzodiazepine-GABA,Receptors, Diazepam,Receptors, GABA-Benzodiazepine,Receptors, Muscimol,Benzodiazepine Receptor,Benzodiazepine Receptors,Benzodiazepine-GABA Receptor,Diazepam Receptor,Diazepam Receptors,GABA(A) Receptor,GABA-A Receptor,GABA-A Receptor alpha Subunit,GABA-A Receptor beta Subunit,GABA-A Receptor delta Subunit,GABA-A Receptor epsilon Subunit,GABA-A Receptor gamma Subunit,GABA-A Receptor rho Subunit,GABA-Benzodiazepine Receptor,GABA-Benzodiazepine Receptors,Muscimol Receptor,Muscimol Receptors,delta Subunit, GABA-A Receptor,epsilon Subunit, GABA-A Receptor,gamma-Aminobutyric Acid Subtype A Receptors,Benzodiazepine GABA Receptor,Benzodiazepine Gaba Receptors,GABA A Receptor,GABA A Receptor alpha Subunit,GABA A Receptor beta Subunit,GABA A Receptor delta Subunit,GABA A Receptor epsilon Subunit,GABA A Receptor gamma Subunit,GABA A Receptor rho Subunit,GABA A Receptors,GABA Benzodiazepine Receptor,GABA Benzodiazepine Receptors,Receptor, Benzodiazepine,Receptor, Benzodiazepine-GABA,Receptor, Diazepam,Receptor, GABA-A,Receptor, GABA-Benzodiazepine,Receptor, Muscimol,Receptors, Benzodiazepine GABA,Receptors, GABA A,Receptors, GABA Benzodiazepine,delta Subunit, GABA A Receptor,epsilon Subunit, GABA A Receptor,gamma Aminobutyric Acid Subtype A Receptors
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding

Related Publications

J M Maloteaux, and M A Luabeya, and M A Vanisberg, and E C Laterre, and P M Laduron, and F Javoy-Agid, and Y Agid
April 1994, Brain research,
J M Maloteaux, and M A Luabeya, and M A Vanisberg, and E C Laterre, and P M Laduron, and F Javoy-Agid, and Y Agid
May 1985, Archives of internal medicine,
J M Maloteaux, and M A Luabeya, and M A Vanisberg, and E C Laterre, and P M Laduron, and F Javoy-Agid, and Y Agid
May 2000, Neurology,
J M Maloteaux, and M A Luabeya, and M A Vanisberg, and E C Laterre, and P M Laduron, and F Javoy-Agid, and Y Agid
August 1998, Journal of neurology, neurosurgery, and psychiatry,
J M Maloteaux, and M A Luabeya, and M A Vanisberg, and E C Laterre, and P M Laduron, and F Javoy-Agid, and Y Agid
March 2012, Movement disorders : official journal of the Movement Disorder Society,
J M Maloteaux, and M A Luabeya, and M A Vanisberg, and E C Laterre, and P M Laduron, and F Javoy-Agid, and Y Agid
January 1994, Journal of neural transmission. Supplementum,
J M Maloteaux, and M A Luabeya, and M A Vanisberg, and E C Laterre, and P M Laduron, and F Javoy-Agid, and Y Agid
August 2015, Movement disorders : official journal of the Movement Disorder Society,
J M Maloteaux, and M A Luabeya, and M A Vanisberg, and E C Laterre, and P M Laduron, and F Javoy-Agid, and Y Agid
January 2016, Frontiers in aging neuroscience,
J M Maloteaux, and M A Luabeya, and M A Vanisberg, and E C Laterre, and P M Laduron, and F Javoy-Agid, and Y Agid
June 2017, Movement disorders : official journal of the Movement Disorder Society,
J M Maloteaux, and M A Luabeya, and M A Vanisberg, and E C Laterre, and P M Laduron, and F Javoy-Agid, and Y Agid
January 2016, European neurology,
Copied contents to your clipboard!